Hukyndra®
ACTIVE PRINCIPLE:
Adalimumab
INDICATION:
Psoriasic arthritis
Juvenile rheumatoid arthritis
Rheumatoid Arthritis
Ulcerative colitis
Crohn's disease
Hidradenitis suppurativa
Psoriasis
Ankylosing spondylitis
Uveitis
DATE:
15/1/2021
STATUS:
Authorized